Navigation Links
Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
Date:6/26/2012

MOUNTAIN VIEW, Calif., June 26, 2012 /PRNewswire/ -- Based on its recent analysis of the clinical diagnostics market,  Frost & Sullivan recognizes GenPath Diagnostics, a business unit of BioReference Laboratories, Inc. with the 2012 North American Frost & Sullivan Award for Company of the Year. As a BioReference specialized cancer laboratory, GenPath is a major factor to the Company's impressive growth trajectory—18 years of 20% Compound Annual Growth Rate (CAGR) in revenue.

GenPath provides complete cancer laboratory testing in addition to novel and proprietary tests. With the entire cancer workup conducted in-house, GenPath delivers superior turn-around-time compared to other commercial laboratories. In addition to standard analysis including morphological examination, flow cytometry, and advanced stains, GenPath also offers proprietary cancer diagnostic testing like the OnkoMatch™ solid tumor genotyping test.

OnkoMatch™ is the culmination of state-of-the-art cancer research and provides oncologists actionable information. Patients are matched with open clinical trials based on their tumor profile. "OnkoMatch™ clearly meets an unmet need in lung cancer patients and also benefits other solid tumor cancers, "said Frost & Sullivan Industry Analyst Winny Tan.

GenPath exclusively licensed the tumor genotyping technology and protocol—upon which OnkoMatch™ is based—from leading cancer research center Massachusetts General Hospital and is the first and only commercial laboratory to offer the test nationally. OnkoMatch™ bridges widely-used single mutation tests with the future of highly complex testing, like whole genome sequencing that is anticipated to reach the clinical markets in the next few years.

Frost & Sullivan independent benchmarking across market participants concludes that the OnkoMatch™ test provides tremendous value by profiling 14 relevant oncogenes across 68 loci including the common single mutations EGFR, KRAS, and BRAF. At $995, the OnkoMatch™ provides a superior price point compared to four individual, single mutation tests. In comparison, just EGFR and KRAS tests together can total more than $1,000 at other specialized cancer laboratories. 

GenPath also carefully assessed the test's likelihood for reimbursement.  GenPath notes that OnkoMatch™ has the desirable qualities that payors require, including growing adoption, a clear result point to clinical trials, and CPT coding that limits over testing. "GenPath's smart reimbursement path for OnkoMatch™ exhibits industry savvy that provides it with a leading competitive edge over other commercial laboratories." noted Tan.

Overall, the market potential for OnkoMatch™ is large with lung, colon, and breast cancers accounting for more than 700,000 new patients per year.  A significant portion of these patients may benefit from tumor genotyping, particularly patients in late stages with few treatment options left. Since the OnkoMatch™ launch in January customer feedback has been extremely positive. Oncologists agree that the future of personalized medicine is based on a patient's tumor genetics. The patient benefits by being informed of relevant open clinical trials based on their tumor profile and their eligibility for drugs upon FDA approval.

Despite its tremendous growth, GenPath still maintains the personalization of a boutique laboratory.  With 45 pathologists on staff, a single pathologist is assigned per case and integrates all test results into a final diagnosis on a single report. Furthermore, GenPath's Chief Medical Officer, James Weisberger MD, personally consults on complex cases. Each patient case receives an expert review from a GenPath pathologist who is committed to providing the most complete and accurate diagnosis.

In recognition of its strategic excellence, growth, and commitment to quality, GenPath is the worthy recipient of the 2012 Frost & Sullivan Award for Company of the Year in clinical diagnostics. Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of growth strategy and implementation. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About GenPath Diagnostics

GenPath Diagnostics is part of BioReference Laboratories, Inc. (BRLI).  BRLI is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.  We are the fourth largest full-service laboratory in the United States and the largest independent regional laboratory in the northeastern market.  BRLI offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases.  BRLI primarily focuses on esoteric testing, molecular diagnostics, oncology, women's health and correctional health care. 

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation, including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

Join Us: Join our community

Subscribe: Newsletter on "the next big thing"

Register: Gain access to visionary innovation

Contact:

Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

 


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
2. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
3. Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market
4. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
5. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
6. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
9. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
10. Fifth Cycle of Probiotics & Microbiota Research Grant Announced
11. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):